|Bid||49.26 x 1000|
|Ask||49.50 x 900|
|Day's range||47.66 - 52.61|
|52-week range||3.54 - 61.50|
|Beta (5Y monthly)||0.82|
|PE ratio (TTM)||N/A|
|Earnings date||11 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||49.20|
Between a big biotech with the leading COVID-19 therapy and a small biotech with a promising COVID-19 vaccine candidate, which stock wins?
What happened Shares of Novavax (NASDAQ: NVAX) were soaring 14.9% as of 3 p.m. EDT on Monday. The big jump came after B. Riley FBR analyst Mayank Mamtani boosted his 12-month price target on the biotech stock to $61 per share from $53.
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
Speculators are buying up shares of Novavax, based on a vast market opportunity for its COVID-19 vaccine. But there's even better news that largely mitigates any downside risk.
If all goes according to plan, Novavax anticipates being able to produce 100 million doses in 2020, mostly for frontline workers, and 1 billion doses by 2021.
These three stocks are leaders in the fight against COVID-19 and have compelling growth prospects beyond their coronavirus programs.
After acquiring a Czech company, the clinical-stage biotech will be able to churn out more than 1 billion doses of its SARS-CoV-2 vaccine candidate next year -- if it works.
Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
Wall Street is rallying this quarter with the S&P 500 reclaiming its 3,000 level.
The U.S. company said on Wednesday it would buy Czech Republic-based Praha Vaccines, a unit of India's Cyrus Poonawalla Group, which also owns Serum Institute, for $167 million in cash. Novavax is one of several companies in the race to develop a vaccine for COVID-19, the disease caused by the novel coronavirus, that has no current treatment or vaccine and has already killed about 350,000 people.
The three major indexes closed in the green on Tuesday, as investors remained hopeful about coronavirus vaccine and that economies around the globe were recovering from the pandemic-driven lockdown over the past few months.
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
Novavax (NASDAQ: NVAX) announced on Monday that it had begun enrolling participants in a phase 1/2 clinical trial of its coronavirus vaccine candidate NVX-CoV2373. The vaccine candidate demonstrated promising results in preclinical testing, including a significant immune system response and high levels of neutralizing antibodies, which bind to the novel coronavirus and block infection. The clinical study will consist of two parts.
Chief among positives for the market is a new vaccine candidate for COVID-19 from Novavax (NVAX), which is launching its human trials in Australia.
As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.
Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.
Shares of Novavax (NASDAQ: NVAX), a clinical-stage vaccine company, are poised to continue their amazing run today. Novavax's shares are heating up yet again this morning in response to the official start of the combined phase 1/2 trial for the company's COVID-19 vaccine candidate, NVX‑CoV2373. Novavax's shares have now gained well over 1,000% since the start of 2020, thanks mainly to the excitement surrounding NVX‑CoV2373.
As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.